| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Medical Services, Department of Veterans Affairs, Iowa City, IA 52246; and
Department of Internal Medicine (Rheumatology), University of Iowa College of Medicine, Iowa City, IA 52242
Isolated murine splenic B cells undergo spontaneous apoptosis. Motifs containing unmethylated CpG dinucleotides in bacterial DNA or in synthetic oligodeoxynucleotides (ODN) are known to activate murine B cells. Now we show that ODN that induce spleen B cell cycle entry also inhibit spontaneous apoptosis in a sequence-specific fashion. Reversal of the CG to GC abolished activity. Methylation of the central cytosine decreased activity. When CpG is preceded by a cytosine or followed by a guanine, activity was abolished. Other substitutions at the same positions had no effect. Dose-response curves for apoptosis protection and G1 entry suggested that a uniform population of ODN recognition sites controlled downstream ODN effects. A CpG ODN with a nuclease-resistant phosphorothioate backbone (S-ODN) was also active, and increased the levels of c-myc, egr-1,c-jun, bclXL, and bax mRNA and c-Myc, c-Jun, Bax, and BclXL protein in spleen B cells. Levels of c-myb, myn, c-Ki-ras, and bcl2 mRNA remained unchanged. When protein synthesis was inhibited, at 16 h ODN-induced cell cycle entry was abolished and apoptosis protection was partially preserved. Under these conditions, c-Myc was still present, but c-Jun and BclXL were not detected. Our results suggest that CpG containing ODN motifs provide signals for both survival and cell cycle entry. Single base changes determine whether this signal proceeds through a rate-limiting step governing at least two steps in apoptosis (plasma membrane transition, DNA cleavage) and two phases of the cell cycle (G1 and S phase entry). This biologic action is associated with increased c-Myc, c-Jun, and BclXL expression.
This article has been cited by other articles:
|
|
 |
|
  Y. Wang, S. A. Blozis, M. Lederman, A. Krieg, A. Landay, and C. J. Miller Enhanced Antibody Responses Elicited by a CpG Adjuvant Do Not Improve the Protective Effect of an Aldrithiol-2-Inactivated Simian Immunodeficiency Virus Therapeutic AIDS Vaccine Clin. Vaccine Immunol., April 1, 2009; 16(4): 499 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ding, L. Wang, J. Marroquin, and J. Yan Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1 Blood, October 1, 2008; 112(7): 2817 - 2825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zheng, N. Asprodites, A. H. Keene, P. Rodriguez, K. D. Brown, and E. Davila TLR9 engagement on CD4 T lymphocytes represses {gamma}-radiation-induced apoptosis through activation of checkpoint kinase response elements Blood, March 1, 2008; 111(5): 2704 - 2713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yotsumoto, K. Saegusa, and Y. Aramaki Endosomal Translocation of CpG-Oligodeoxynucleotides Inhibits DNA-PKcs-Dependent IL-10 Production in Macrophages J. Immunol., January 15, 2008; 180(2): 809 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Wykes, X. Q. Liu, S. Jiang, C. Hirunpetcharat, and M. F. Good Systemic Tumor Necrosis Factor Generated during Lethal Plasmodium Infections Impairs Dendritic Cell Function J. Immunol., September 15, 2007; 179(6): 3982 - 3987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, W. Song, D. K. Czerwinski, B. Varghese, S. Uematsu, S. Akira, A. M. Krieg, and R. Levy Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself J. Immunol., August 15, 2007; 179(4): 2493 - 2500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Krieg Antiinfective Applications of Toll-like Receptor 9 Agonists Proceedings of the ATS, July 1, 2007; 4(3): 289 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-C. Kuo, C.-M. Liang, C.-Y. Lai, and S.-M. Liang Involvement of Heat Shock Protein (Hsp)90beta but Not Hsp90{alpha} in Antiapoptotic Effect of CpG-B Oligodeoxynucleotide J. Immunol., May 15, 2007; 178(10): 6100 - 6108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Darce, B. K. Arendt, S. K. Chang, and D. F. Jelinek Divergent Effects of BAFF on Human Memory B Cell Differentiation into Ig-Secreting Cells J. Immunol., May 1, 2007; 178(9): 5612 - 5622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ertesvag, H.-C. Aasheim, S. Naderi, and H. K. Blomhoff Vitamin A potentiates CpG-mediated memory B-cell proliferation and differentiation: involvement of early activation of p38MAPK Blood, May 1, 2007; 109(9): 3865 - 3872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Kuo, S.-M. Liang, and C.-M. Liang CpG-B Oligodeoxynucleotide Promotes Cell Survival via Up-regulation of Hsp70 to Increase Bcl-xL and to Decrease Apoptosis-inducing Factor Translocation J. Biol. Chem., December 15, 2006; 281(50): 38200 - 38207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Sester, K. Brion, A. Trieu, H. S. Goodridge, T. L. Roberts, J. Dunn, D. A. Hume, K. J. Stacey, and M. J. Sweet CpG DNA Activates Survival in Murine Macrophages through TLR9 and the Phosphatidylinositol 3-Kinase-Akt Pathway J. Immunol., October 1, 2006; 177(7): 4473 - 4480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Donati, B. Mok, A. Chene, H. Xu, M. Thangarajh, R. Glas, Q. Chen, M. Wahlgren, and M. T. Bejarano Increased B cell survival and preferential activation of the memory compartment by a malaria polyclonal B cell activator. J. Immunol., September 1, 2006; 177(5): 3035 - 3044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tengvall, A. Lundqvist, R. J. Eisenberg, G. H. Cohen, and A. M. Harandi Mucosal Administration of CpG Oligodeoxynucleotide Elicits Strong CC and CXC Chemokine Responses in the Vagina and Serves as a Potent Th1-Tilting Adjuvant for Recombinant gD2 Protein Vaccination against Genital Herpes. J. Virol., June 1, 2006; 80(11): 5283 - 5291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Kozak, S. Wrotek, and A. Kozak Pyrogenicity of CpG-DNA in mice: role of interleukin-6, cyclooxygenases, and nuclear factor-{kappa}B Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2006; 290(4): R871 - R880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Blank and Y. Shoenfeld Experimental models of systemic lupus erythematosus: anti-dsDNA in murine lupus Rheumatology, September 1, 2005; 44(9): 1086 - 1089. [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Ashman, J. A. Goeken, J. Drahos, and P. Lenert Sequence requirements for oligodeoxyribonucleotide inhibitory activity Int. Immunol., April 1, 2005; 17(4): 411 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Brummel and P. Lenert Activation of Marginal Zone B Cells from Lupus Mice with Type A(D) CpG-Oligodeoxynucleotides J. Immunol., February 15, 2005; 174(4): 2429 - 2434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Roberts, M. J. Sweet, D. A. Hume, and K. J. Stacey Cutting Edge: Species-Specific TLR9-Mediated Recognition of CpG and Non-CpG Phosphorothioate-Modified Oligonucleotides J. Immunol., January 15, 2005; 174(2): 605 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Anders, B. Banas, and D. Schlondorff Signaling Danger: Toll-Like Receptors and their Potential Roles in Kidney Disease J. Am. Soc. Nephrol., April 1, 2004; 15(4): 854 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Raghavan, J. Nystrom, M. Fredriksson, J. Holmgren, and A. M. Harandi Orally Administered CpG Oligodeoxynucleotide Induces Production of CXC and CC Chemokines in the Gastric Mucosa and Suppresses Bacterial Colonization in a Mouse Model of Helicobacter pylori Infection Infect. Immun., December 1, 2003; 71(12): 7014 - 7022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Yeo, J.-G. Yoon, and A.-K. Yi Myeloid Differentiation Factor 88-dependent Post-transcriptional Regulation of Cyclooxygenase-2 Expression by CpG DNA: TUMOR NECROSIS FACTOR-{alpha} RECEPTOR-ASSOCIATED FACTOR 6, A DIVERGING POINT IN THE Toll-LIKE RECEPTOR 9-SIGNALING J. Biol. Chem., October 17, 2003; 278(42): 40590 - 40600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-K. Yi, J.-G. Yoon, and A. M. Krieg Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-{kappa}B activation pathways: regulation by mitogen-activated protein kinases Int. Immunol., May 1, 2003; 15(5): 577 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Stacey, G. R. Young, F. Clark, D. P. Sester, T. L. Roberts, S. Naik, M. J. Sweet, and D. A. Hume The Molecular Basis for the Lack of Immunostimulatory Activity of Vertebrate DNA J. Immunol., April 1, 2003; 170(7): 3614 - 3620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Yeo, J.-G. Yoon, S.-C. Hong, and A.-K. Yi CpG DNA Induces Self and Cross-Hyporesponsiveness of RAW264.7 Cells in Response to CpG DNA and Lipopolysaccharide: Alterations in IL-1 Receptor-Associated Kinase Expression J. Immunol., January 15, 2003; 170(2): 1052 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Harandi, K. Eriksson, and J. Holmgren A Protective Role of Locally Administered Immunostimulatory CpG Oligodeoxynucleotide in a Mouse Model of Genital Herpes Infection J. Virol., December 20, 2002; 77(2): 953 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-K. Yi, J.-G. Yoon, S.-J. Yeo, S.-C. Hong, B. K. English, and A. M. Krieg Role of Mitogen-Activated Protein Kinases in CpG DNA-Mediated IL-10 and IL-12 Production: Central Role of Extracellular Signal-Regulated Kinase in the Negative Feedback Loop of the CpG DNA-Mediated Th1 Response J. Immunol., May 1, 2002; 168(9): 4711 - 4720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Gerdts, M. Snider, R. Brownlie, L. A. Babiuk, and P. J. Griebel Oral DNA Vaccination In Utero Induces Mucosal Immunity and Immune Memory in the Neonate J. Immunol., February 15, 2002; 168(4): 1877 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-K. Yi, J.-G. Yoon, S.-C. Hong, T. W. Redford, and A. M. Krieg Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-{alpha} production through activation of NF-{kappa}B Int. Immunol., November 1, 2001; 13(11): 1391 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. K. Ballas, A. M. Krieg, T. Warren, W. Rasmussen, H. L. Davis, M. Waldschmidt, and G. J. Weiner Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs J. Immunol., November 1, 2001; 167(9): 4878 - 4886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. K. M. Shoda, K. A. Kegerreis, C. E. Suarez, W. Mwangi, D. P. Knowles, and W. C. Brown Immunostimulatory CpG-modified plasmid DNA enhances IL-12, TNF-{alpha}, and NO production by bovine macrophages J. Leukoc. Biol., July 1, 2001; 70(1): 103 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Peckham, E. Andersen-Nissen, F. D. Finkelman, L. L. Stunz, and R. F. Ashman Difference in apoptosis induction between surface IgD and IgM Int. Immunol., March 1, 2001; 13(3): 285 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Sester, S. Naik, S. J. Beasley, D. A. Hume, and K. J. Stacey Phosphorothioate Backbone Modification Modulates Macrophage Activation by CpG DNA J. Immunol., October 15, 2000; 165(8): 4165 - 4173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Guinness, J. L. Kenney, M. Reiss, and J. Lacy Bcl-2 Antisense Oligodeoxynucleotide Therapy of Epstein-Barr Virus-associated Lymphoproliferative Disease in Severe Combined Immunodeficient Mice Cancer Res., October 1, 2000; 60(19): 5354 - 5358. [Abstract] [Full Text]
|
|
|
|
|
|
G. Hartmann, R. D. Weeratna, Z. K. Ballas, P. Payette, S. Blackwell, I. Suparto, W. L. Rasmussen, M. Waldschmidt, D. Sajuthi, R. H. Purcell, et al. Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo J. Immunol., February 1, 2000; 164(3): 1617 - 1624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Decker, F. Schneller, T. Sparwasser, T. Tretter, G. B. Lipford, H. Wagner, and C. Peschel Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells Blood, February 1, 2000; 95(3): 999 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hartmann and A. M. Krieg Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells J. Immunol., January 15, 2000; 164(2): 944 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Sester, S. J. Beasley, M. J. Sweet, L. F. Fowles, S. L. Cronau, K. J. Stacey, and D. A. Hume Bacterial/CpG DNA Down-Modulates Colony Stimulating Factor-1 Receptor Surface Expression on Murine Bone Marrow-Derived Macrophages with Concomitant Growth Arrest and Factor-Independent Survival J. Immunol., December 15, 1999; 163(12): 6541 - 6550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-K. Yi, D. W. Peckham, R. F. Ashman, and A. M. Krieg CpG DNA rescues B cells from apoptosis by activating NF{kappa}B and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway Int. Immunol., December 1, 1999; 11(12): 2015 - 2024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Brown, D. M. Estes, S. E. Chantler, K. A. Kegerreis, and C. E. Suarez DNA and a CpG Oligonucleotide Derived from Babesia bovis Are Mitogenic for Bovine B Cells Infect. Immun., November 1, 1998; 66(11): 5423 - 5432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Krieg, T. Wu, R. Weeratna, S. M. Efler, L. Love-Homan, L. Yang, A.-K. Yi, D. Short, and H. L. Davis Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs PNAS, October 13, 1998; 95(21): 12631 - 12636. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
